Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Long-term Activity Ratios (Summary)
Net Fixed Asset Turnover
Total Asset Turnover
Equity Turnover

Eli Lilly & Co., long-term (investment) activity ratios (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Net fixed asset turnover	2.88	2.92	2.83	2.90	2.96	3.08	2.75	2.75	2.72	2.61	2.59	2.61	2.56	2.56	2.57	2.53	2.55	2.51	2.48	—	—	—
Total asset turnover	0.55	0.56	0.57	0.60	0.60	0.63	0.56	0.54	0.56	0.53	0.51	0.52	0.54	0.57	0.55	0.55	0.56	0.58	0.56	—	—	—
Equity turnover	5.61	7.50	8.56	6.69	8.35	9.66	2.50	1.86	2.07	1.61	1.97	1.51	1.56	1.54	1.52	1.34	1.41	1.34	1.37	—	—	—

Long-term activity ratio	Description	The company
Net fixed asset turnover	An activity ratio calculated as total revenue divided by net fixed assets.	Eli Lilly & Co.’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020 not reaching Q4 2019 level.
Total asset turnover	An activity ratio calculated as total revenue divided by total assets.	Eli Lilly & Co.’s total asset turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Equity turnover	An activity ratio calculated as total revenue divided by shareholders’ equity.	Eli Lilly & Co.’s equity turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Eli Lilly & Co., net fixed asset turnover calculation (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selected Financial Data (US$ in thousands)
Revenue	5,499,400	5,859,800	6,114,000	5,476,600	5,636,700	5,092,200	6,438,600	6,061,900	6,355,200	5,700,000	6,160,700	5,658,000	5,824,300	5,228,300	5,760,500	5,191,700	5,404,800	4,865,100	5,375,600	4,959,700	4,978,700	4,644,700
Property and equipment, net of accumulated depreciation	7,981,100	7,897,900	7,872,900	7,801,500	7,847,500	7,780,000	8,919,500	8,814,100	8,770,800	8,958,200	8,826,500	8,598,500	8,582,800	8,425,500	8,252,600	8,251,900	8,066,100	8,033,100	8,053,500	8,075,300	8,022,600	7,950,700
Long-term Activity Ratio
Net fixed asset turnover¹	2.88	2.92	2.83	2.90	2.96	3.08	2.75	2.75	2.72	2.61	2.59	2.61	2.56	2.56	2.57	2.53	2.55	2.51	2.48	—	—	—
Benchmarks
Net Fixed Asset Turnover, Competitors²
Abbott Laboratories	3.77	4.06	3.97	4.01	3.95	4.03	4.04	4.08	3.98	3.71	3.60	3.48	3.24	3.07	3.66	3.61	3.53	3.49	3.56	—	—	—
AbbVie Inc.	7.38	11.50	11.23	11.36	11.33	11.42	11.36	10.91	11.10	10.47	10.07	10.11	10.05	10.04	9.85	9.57	9.46	9.16	8.91	—	—	—
Amgen Inc.	4.78	4.68	4.51	4.55	4.58	4.59	4.54	4.51	4.48	4.44	4.37	4.45	4.41	4.41	4.41	4.39	4.41	4.36	4.27	—	—	—
Biogen Inc.	4.35	4.39	4.43	4.54	4.57	4.58	3.74	3.74	3.78	3.78	3.86	3.95	4.14	4.42	4.58	4.78	4.88	4.84	4.92	—	—	—
Bristol-Myers Squibb Co.	6.03	5.07	4.18	5.00	4.92	4.67	4.49	4.33	4.25	4.16	4.15	4.10	4.09	3.98	3.90	3.86	3.83	3.80	3.75	—	—	—
Gilead Sciences Inc.	4.70	4.90	4.91	5.03	5.16	5.31	5.41	5.76	6.23	7.11	7.79	8.72	9.31	9.80	10.45	11.48	12.29	13.34	14.13	—	—	—
Illumina Inc.	3.77	4.00	3.99	3.95	3.99	3.99	3.10	3.06	3.00	2.99	2.96	3.01	2.97	3.30	3.36	3.74	4.52	5.85	6.48	—	—	—
Johnson & Johnson	4.57	4.75	4.65	4.79	4.72	4.80	4.79	4.89	4.85	4.62	4.50	4.47	4.41	4.46	4.52	4.45	4.44	4.40	4.41	—	—	—
Merck & Co. Inc.	2.99	3.15	3.11	3.22	3.20	3.19	3.18	3.27	3.27	3.24	3.23	3.27	3.31	3.32	3.31	3.32	3.29	3.19	3.16	—	—	—
Pfizer Inc.	3.49	3.61	3.71	3.87	3.97	4.00	4.01	3.80	3.83	3.77	3.79	3.89	3.91	3.97	3.97	4.01	3.84	3.75	3.55	—	—	—
Regeneron Pharmaceuticals Inc.	2.64	2.71	2.72	2.75	2.70	2.65	2.61	2.52	2.52	2.53	2.49	2.43	2.32	2.19	2.33	2.53	2.62	2.66	2.57	—	—	—
Vertex Pharmaceuticals Inc.	7.42	6.55	5.59	4.93	4.72	4.40	3.75	3.50	3.21	3.02	3.15	3.02	2.88	2.85	2.44	2.42	2.26	1.87	1.48	—	—	—
Zoetis Inc.	3.15	3.21	3.23	3.39	3.48	3.51	3.51	3.68	3.80	3.75	3.70	3.69	3.70	3.62	3.54	3.53	3.62	3.66	3.65	—	—	—

¹ Q2 2020 Calculation
Net fixed asset turnover = (Revenue_{Q2 2020} + Revenue_{Q1 2020} + Revenue_{Q4 2019} + Revenue_{Q3 2019}) ÷ Property and equipment, net of accumulated depreciation
= (5,499,400 + 5,859,800 + 6,114,000 + 5,476,600) ÷ 7,981,100 = 2.88

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Net fixed asset turnover	An activity ratio calculated as total revenue divided by net fixed assets.	Eli Lilly & Co.’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020 not reaching Q4 2019 level.

Eli Lilly & Co., total asset turnover calculation (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selected Financial Data (US$ in thousands)
Revenue	5,499,400	5,859,800	6,114,000	5,476,600	5,636,700	5,092,200	6,438,600	6,061,900	6,355,200	5,700,000	6,160,700	5,658,000	5,824,300	5,228,300	5,760,500	5,191,700	5,404,800	4,865,100	5,375,600	4,959,700	4,978,700	4,644,700
Total assets	41,967,000	41,102,800	39,286,100	37,893,100	38,666,400	38,006,800	43,908,400	44,625,100	42,359,200	44,355,600	44,981,000	43,010,400	40,946,500	37,624,300	38,805,900	37,590,300	36,475,300	34,691,800	35,568,900	36,304,700	36,036,600	35,653,900
Long-term Activity Ratio
Total asset turnover¹	0.55	0.56	0.57	0.60	0.60	0.63	0.56	0.54	0.56	0.53	0.51	0.52	0.54	0.57	0.55	0.55	0.56	0.58	0.56	—	—	—
Benchmarks
Total Asset Turnover, Competitors²
Abbott Laboratories	0.46	0.48	0.47	0.46	0.45	0.45	0.46	0.42	0.43	0.40	0.36	0.35	0.33	0.31	0.40	0.52	0.52	0.51	0.49	—	—	—
AbbVie Inc.	0.24	0.37	0.37	0.55	0.57	0.58	0.55	0.49	0.50	0.43	0.40	0.40	0.40	0.40	0.39	0.38	0.37	0.44	0.43	—	—	—
Amgen Inc.	0.36	0.37	0.37	0.37	0.38	0.35	0.34	0.33	0.33	0.31	0.27	0.27	0.28	0.28	0.28	0.28	0.29	0.28	0.29	—	—	—
Biogen Inc.	0.57	0.55	0.53	0.52	0.54	0.52	0.53	0.52	0.54	0.48	0.52	0.51	0.54	0.54	0.50	0.52	0.52	0.53	0.55	—	—	—
Bristol-Myers Squibb Co.	0.27	0.24	0.20	0.42	0.43	0.67	0.64	0.65	0.66	0.64	0.62	0.61	0.61	0.61	0.58	0.55	0.54	0.53	0.52	—	—	—
Gilead Sciences Inc.	0.39	0.37	0.36	0.37	0.35	0.35	0.34	0.34	0.35	0.37	0.37	0.42	0.47	0.50	0.53	0.55	0.64	0.68	0.62	—	—	—
Illumina Inc.	0.46	0.49	0.48	0.49	0.49	0.46	0.48	0.48	0.53	0.53	0.52	0.51	0.51	0.53	0.56	0.56	0.58	0.59	0.60	—	—	—
Johnson & Johnson	0.51	0.53	0.52	0.53	0.52	0.54	0.53	0.52	0.52	0.50	0.49	0.48	0.47	0.50	0.51	0.51	0.51	0.52	0.53	—	—	—
Merck & Co. Inc.	0.52	0.57	0.55	0.55	0.53	0.52	0.51	0.49	0.49	0.47	0.46	0.43	0.43	0.41	0.42	0.41	0.41	0.40	0.39	—	—	—
Pfizer Inc.	0.28	0.30	0.31	0.31	0.34	0.35	0.34	0.32	0.32	0.32	0.31	0.30	0.31	0.31	0.31	0.30	0.31	0.31	0.29	—	—	—
Regeneron Pharmaceuticals Inc.	0.55	0.51	0.53	0.55	0.55	0.54	0.57	0.59	0.62	0.65	0.67	0.63	0.65	0.64	0.70	0.69	0.75	0.75	0.73	—	—	—
Vertex Pharmaceuticals Inc.	0.53	0.54	0.50	0.48	0.49	0.50	0.49	0.61	0.60	0.61	0.70	0.72	0.65	0.69	0.59	0.64	0.61	0.52	0.41	—	—	—
Zoetis Inc.	0.49	0.55	0.54	0.55	0.55	0.54	0.54	0.55	0.65	0.63	0.62	0.55	0.64	0.65	0.64	0.63	0.65	0.65	0.60	—	—	—

¹ Q2 2020 Calculation
Total asset turnover = (Revenue_{Q2 2020} + Revenue_{Q1 2020} + Revenue_{Q4 2019} + Revenue_{Q3 2019}) ÷ Total assets
= (5,499,400 + 5,859,800 + 6,114,000 + 5,476,600) ÷ 41,967,000 = 0.55

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Total asset turnover	An activity ratio calculated as total revenue divided by total assets.	Eli Lilly & Co.’s total asset turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Eli Lilly & Co., equity turnover calculation (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selected Financial Data (US$ in thousands)
Revenue	5,499,400	5,859,800	6,114,000	5,476,600	5,636,700	5,092,200	6,438,600	6,061,900	6,355,200	5,700,000	6,160,700	5,658,000	5,824,300	5,228,300	5,760,500	5,191,700	5,404,800	4,865,100	5,375,600	4,959,700	4,978,700	4,644,700
Total Eli Lilly and Company shareholders’ equity	4,092,900	3,078,800	2,606,900	3,382,500	2,780,500	2,480,300	9,828,700	13,076,600	11,555,200	14,527,000	11,592,200	14,890,300	14,100,800	14,031,000	14,007,700	15,589,200	14,637,300	15,009,900	14,571,300	15,221,400	14,670,300	14,919,800
Long-term Activity Ratio
Equity turnover¹	5.61	7.50	8.56	6.69	8.35	9.66	2.50	1.86	2.07	1.61	1.97	1.51	1.56	1.54	1.52	1.34	1.41	1.34	1.37	—	—	—
Benchmarks
Equity Turnover, Competitors²
Abbott Laboratories	1.03	1.06	1.03	0.99	0.98	0.99	1.00	0.99	0.97	0.91	0.89	0.78	0.75	0.71	1.02	1.00	0.99	0.98	0.96	—	—	—
AbbVie Inc.	2.46	—	—	—	—	—	—	—	—	8.33	5.54	4.08	4.44	5.25	5.53	3.90	4.39	5.12	5.79	—	—	—
Amgen Inc.	2.17	2.41	2.30	2.04	2.07	2.07	1.80	1.54	1.48	1.40	0.86	0.68	0.69	0.71	0.73	0.70	0.72	0.74	0.75	—	—	—
Biogen Inc.	1.28	1.15	1.08	1.02	1.09	1.00	1.03	0.96	1.05	0.90	0.97	0.92	1.01	1.00	0.94	0.94	0.99	1.06	1.15	—	—	—
Bristol-Myers Squibb Co.	0.71	0.62	0.51	1.37	1.49	1.53	1.61	1.62	1.75	1.64	1.77	1.39	1.38	1.38	1.20	1.18	1.18	1.18	1.16	—	—	—
Gilead Sciences Inc.	1.21	1.01	0.98	1.07	0.97	1.00	1.01	0.96	1.05	1.18	1.26	1.09	1.24	1.40	1.59	1.85	2.06	2.42	1.73	—	—	—
Illumina Inc.	0.73	0.77	0.77	0.78	0.79	0.85	0.89	0.93	0.95	0.98	1.00	0.91	0.92	0.95	1.09	1.06	1.13	1.13	1.20	—	—	—
Johnson & Johnson	1.28	1.35	1.38	1.40	1.34	1.38	1.37	1.26	1.28	1.24	1.27	1.01	1.01	1.03	1.02	0.98	0.98	0.97	0.98	—	—	—
Merck & Co. Inc.	1.71	1.83	1.81	1.71	1.61	1.56	1.58	1.29	1.27	1.21	1.17	1.04	1.01	1.00	0.99	0.91	0.91	0.90	0.88	—	—	—
Pfizer Inc.	0.76	0.78	0.82	0.81	0.90	0.92	0.85	0.75	0.76	0.72	0.74	0.86	0.90	0.90	0.89	0.84	0.83	0.81	0.75	—	—	—
Regeneron Pharmaceuticals Inc.	0.88	0.66	0.71	0.73	0.74	0.73	0.77	0.81	0.86	0.92	0.96	0.91	0.95	1.02	1.09	1.05	1.14	1.18	1.12	—	—	—
Vertex Pharmaceuticals Inc.	0.72	0.75	0.68	0.69	0.68	0.69	0.69	0.97	0.98	1.01	1.23	1.28	1.28	1.35	1.47	1.63	1.59	1.35	1.10	—	—	—
Zoetis Inc.	2.13	2.30	2.31	2.30	2.51	2.55	2.67	2.70	2.84	2.78	3.00	2.58	2.93	3.08	3.29	3.08	3.58	4.14	4.46	—	—	—

¹ Q2 2020 Calculation
Equity turnover = (Revenue_{Q2 2020} + Revenue_{Q1 2020} + Revenue_{Q4 2019} + Revenue_{Q3 2019}) ÷ Total Eli Lilly and Company shareholders’ equity
= (5,499,400 + 5,859,800 + 6,114,000 + 5,476,600) ÷ 4,092,900 = 5.61

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Equity turnover	An activity ratio calculated as total revenue divided by shareholders’ equity.	Eli Lilly & Co.’s equity turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Eli Lilly & Co. (NYSE:LLY)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Long-term Activity Ratios (Summary)

Net Fixed Asset Turnover

Total Asset Turnover

Equity Turnover

Eli Lilly & Co. (NYSE:LLY)

Analysis of Long-term (Investment) Activity RatiosQuarterly Data

Long-term Activity Ratios (Summary)

Net Fixed Asset Turnover

Total Asset Turnover

Equity Turnover

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data